Prevention Study in Adult Patients Suffering From Migraine Headaches
Study MPX111381: A Dose-ranging Study Evaluating the Efficacy, Safety and Tolerability of GSK1838262 (XP13512) in the Prophylactic Treatment of Migraine Headache
Sponsor: GlaxoSmithKline
This PHASE2 trial investigates Migraine and Migraine Disorders and is currently completed. GlaxoSmithKline leads this study, which shows 7 recorded versions since 2008 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Aug 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
- XenoPort, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Albany, United States, Alexandria, United States, Anaheim, United States, Atlanta, United States, Bay Roberts, Canada, Birmingham, United States, Brampton, Canada, Charleston, United States, Chicago, United States, Cleveland, United States and 41 more location s